14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BHST vs BLTE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Belite Bio, Inc (BLTE) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (39.7/100 SELL vs. 58.2/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality), while BHST wins 4–1 across the 6-pillar growth and valuation breakdown. BHST trades at $1.30 (N/M Forward P/E, -18.0% operating margin) versus BLTE at $127.38 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. BLTE 39.7/100 SELL), BLTE captures the overall institutional head-to-head verdict (6–2 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -18.0% operating margin) and revenue trajectory (+0.0% vs. +3.8% YoY).
Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile BLTE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHST vs BLTE. Trailing 12-month operating profitability (BHST -18.0% vs BLTE 0.0%) and valuation multiples (BHST N/M vs BLTE N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $5.4B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BHST vs BLTE Key Questions & Quantitative Answers
As of Nov 20, 2026, Belite Bio, Inc (BLTE) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (39.7/100 SELL vs. 58.2/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality), while BHST wins 4–1 across the 6-pillar growth and valuation breakdown. BHST trades at $1.30 (N/M Forward P/E, -18.0% operating margin) versus BLTE at $127.38 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. BLTE 39.7/100 SELL), BLTE captures the overall institutional head-to-head verdict (6–2 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -18.0% operating margin) and revenue trajectory (+0.0% vs. +3.8% YoY). Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile BLTE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BHST leads the Growth & Scale pillar: BHST posts +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin), compared with BLTE at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BHST generates $35M in USD-normalized revenue versus N/A for BLTE. In operating R&D and SG&A reinvestment, BHST deploys 77.0% of Rev ($27M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BLTE.
BHST screens cheaper on headline valuation multiples. BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin), whereas BLTE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHST (-142.5% ROE) versus BLTE (-21.2% ROE) capital efficiency.
In options market volatility and institutional positioning, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk). By comparison, BLTE carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.31β · 71% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.